Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biomaven	4/25/2008 11:44:26 PM
	Read Replies (1) of 52153

Some interesting discussion about RIGL on the munch thread, starting approximately here: Message 24522534 Thought I would attempt to continue this here instead. With regards to efficacy RIGL highlighted the fact that during randomized treatment patients with dose reductions continued to experience progressive improvement in ACR scores and actually had greater improvements in ACR 20, 50 and 70 scores than patients not requiring dose reduction. That's very interesting. I had been concerned by an apparently narrow therapeutic window, but this suggests that maybe it's just a question of individualized dose titration instead. The upcoming b-cell lymphoma results should be interesting - there's an interesting recent article suggesting the theoretical basis for how this might work. BTW, curcumin (from turmeric) appears to be something of a SYK inhibitor too. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next